YRDC and neoplasm: Meanwhile, YRDC overexpression cells showed more sensitivity to lenvatinib compared with its control cells when evaluated by tumor weight (78 vs. 67%) (Figure 4C), however, not significantly different when evaluated by tumor volume (Figure 4B).